Nadira Hamid, MD

Internal Medicine, Cardiovascular Disease

Nadira Hamid, MD recently joined the Minneapolis Heart Institute and the Cardiovascular Imaging Research Center at MHIF. She's a non-invasive, board certified cardiologist who specializes in Echocardiography. She is board certified in both echocardiography and cardiac computed tomography.

Dr. Hamid graduated from the Royal College of Surgeons in Ireland (Dublin). She completed her postgraduate degrees with the Royal College of Physicians in Ireland (MRCPI) and Royal College of Physicians in United Kingdom (MRCP UK). She completed her residencies in Dublin, Ireland and then went on to complete her cardiology fellowship at the National Heart Centre Singapore (NHCS) in Singapore. She also has research training and completed her Master of Clinical Investigation (MCI) from the National University of Singapore. She completed her Advanced Echocardiography fellowship/Interventional Echocardiography fellowship (Structural Heart Interventions) at Columbia University Irving Medical Center in New York.

Back to Imaging Team

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute FoundationĀ® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.